BACKGROUND: In developing countries, there are few data that characterize the disease burden attributable to respiratory syncytial virus (RSV) and clearly define which age group to target for vaccine intervention. METHODS: Six hundred thirty-five children, recruited during the period 2002-2003, were intensively monitored until each experienced 3 epidemics of RSV infection. RSV infection was diagnosed using immunofluorescence of nasal washing specimens collected at each episode of acute respiratory infection. Incidence estimates were adjusted for seasonality of RSV exposure. RESULTS: For 1187 child-years of observation (CYO), a total of 409 (365 primary and 82 repeat) episodes of RSV infection were identified. Adjusted incidence estimates of lower respiratory tract infection (LRTI), severe LRTI, and hospital admission were 90 cases per 1000 CYO, 43 cases per 1000 CYO, and 10 cases per 1000 CYO, respectively, and corresponding estimates among infants were 104 cases per 1000 CYO, 66 cases per 1000 CYO, and 13 cases per 1000 CYO, respectively. The proportion of cases of all-cause LRTI, and severe LRTI and hospitalizations attributable to RSV in the cohort was 13%, 19%, and 5%, respectively. Fifty-five percent to 65% of RSV-associated LRTI and severe LRTI occurred in children aged >6 months. The risk of RSV disease following primary symptomatic infection remained significant beyond the first year of life, and one-quarter of all reinfections were associated with LRTI. CONCLUSIONS: RSV accounts for a substantial proportion of the total respiratory disease in this rural population; we estimate that 85,000 cases of severe LRTI per year occur in infants in Kenya. The majority of this morbidity occurs during late infancy and early childhood--ages at which the risk of disease following infection remains significant. Disease resulting from reinfection is common. Our results inform the debate on the target age group and effectiveness of a vaccine.
BACKGROUND: In developing countries, there are few data that characterize the disease burden attributable to respiratory syncytial virus (RSV) and clearly define which age group to target for vaccine intervention. METHODS: Six hundred thirty-five children, recruited during the period 2002-2003, were intensively monitored until each experienced 3 epidemics of RSV infection. RSV infection was diagnosed using immunofluorescence of nasal washing specimens collected at each episode of acute respiratory infection. Incidence estimates were adjusted for seasonality of RSV exposure. RESULTS: For 1187 child-years of observation (CYO), a total of 409 (365 primary and 82 repeat) episodes of RSV infection were identified. Adjusted incidence estimates of lower respiratory tract infection (LRTI), severe LRTI, and hospital admission were 90 cases per 1000 CYO, 43 cases per 1000 CYO, and 10 cases per 1000 CYO, respectively, and corresponding estimates among infants were 104 cases per 1000 CYO, 66 cases per 1000 CYO, and 13 cases per 1000 CYO, respectively. The proportion of cases of all-cause LRTI, and severe LRTI and hospitalizations attributable to RSV in the cohort was 13%, 19%, and 5%, respectively. Fifty-five percent to 65% of RSV-associated LRTI and severe LRTI occurred in children aged >6 months. The risk of RSV disease following primary symptomatic infection remained significant beyond the first year of life, and one-quarter of all reinfections were associated with LRTI. CONCLUSIONS:RSV accounts for a substantial proportion of the total respiratory disease in this rural population; we estimate that 85,000 cases of severe LRTI per year occur in infants in Kenya. The majority of this morbidity occurs during late infancy and early childhood--ages at which the risk of disease following infection remains significant. Disease resulting from reinfection is common. Our results inform the debate on the target age group and effectiveness of a vaccine.
Authors: Susan E Robertson; Anna Roca; Pedro Alonso; Eric A F Simoes; Cissy B Kartasasmita; David O Olaleye; Georgina N Odaibo; Mark Collinson; Marietjie Venter; Yuwei Zhu; Peter F Wright Journal: Bull World Health Organ Date: 2005-01-05 Impact factor: 9.408
Authors: F Freymuth; A Vabret; F Galateau-Salle; J Ferey; G Eugene; J Petitjean; E Gennetay; J Brouard; M Jokik; J F Duhamel; B Guillois Journal: Clin Diagn Virol Date: 1997-05
Authors: Charlotte F McAuley; Clare Webb; Julie Makani; Alexander Macharia; Sophie Uyoga; Daniel H Opi; Carolyne Ndila; Antony Ngatia; John Anthony G Scott; Kevin Marsh; Thomas N Williams Journal: Blood Date: 2010-06-08 Impact factor: 22.113
Authors: James A Berkley; Patrick Munywoki; Mwanajuma Ngama; Sidi Kazungu; John Abwao; Anne Bett; Ria Lassauniére; Tina Kresfelder; Patricia A Cane; Marietjie Venter; J Anthony G Scott; D James Nokes Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell Journal: Lancet Date: 2010-05-01 Impact factor: 79.321
Authors: D James Nokes; Mwanajuma Ngama; Anne Bett; John Abwao; Patrick Munywoki; Mike English; J Anthony G Scott; Patricia A Cane; Graham F Medley Journal: Clin Infect Dis Date: 2009-11-01 Impact factor: 9.079
Authors: Emelda A Okiro; Mwanajuma Ngama; Ann Bett; Patricia A Cane; Graham F Medley; D James Nokes Journal: Trop Med Int Health Date: 2008-05-08 Impact factor: 2.622
Authors: Thomas N Williams; Sophie Uyoga; Alex Macharia; Carolyne Ndila; Charlotte F McAuley; Daniel H Opi; Salim Mwarumba; Julie Makani; Albert Komba; Moses N Ndiritu; Shahnaaz K Sharif; Kevin Marsh; James A Berkley; J Anthony G Scott Journal: Lancet Date: 2009-09-09 Impact factor: 79.321
Authors: Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes Journal: PLoS One Date: 2009-12-02 Impact factor: 3.240
Authors: Emelda A Okiro; Lisa J White; Mwanajuma Ngama; Patricia A Cane; Graham F Medley; D James Nokes Journal: BMC Infect Dis Date: 2010-01-22 Impact factor: 3.090